American heart journal

publication venue for

Progressive dehiscence and dynamic compression of an aortic root homograft: detection and characterization by transesophageal echocardiography. 1996
Treatment of spontaneous coronary artery dissection with intracoronary stenting. 1996
Physiologic role of atrio-Hisian and nodo-Hisian bypass tracts in supraventricular tachycardia. 1994
Masking of echocardiographic mitral valve prolapse during evolution of dilated cardiomyopathy. 1993
Thallium-201 tomography in the management of exercise-induced coronary spasm. 1992
Myocardial entrapment by lymphoma: a cause of reversible segmental left ventricular dysfunction. 1992
Unstable angina or non-Q wave infarction despite long-term aspirin: response to thrombolytic therapy with implications on mechanisms. 1990
Intracardiac thrombi in patients undergoing electroconvulsive therapy. 1990
Severe hemolytic anemia following mitral valve repair. 1989
Mid-cavity obstruction in apical hypertrophy: Doppler evidence of diastolic intraventricular gradient with higher apical pressure. 1988
Exercise-induced atrioventricular block: report of three cases. 1988
Carcinoid heart disease presenting as right-to-left shunt and congestive heart failure: successful surgical treatment. 1988
Right-to-left intracardiac shunt and constrictive pericarditis following coronary artery bypass surgery. 1987
Unsuspected partial anomalous pulmonary venous drainage in a patient with coronary disease: detection by radionuclide angiography. 1986
Echocardiographic findings of metastatic chondrosarcoma involving the left atrium. 1986
Adverse clinical and hemodynamic effects of oral levodopa in chronic congestive heart failure. 1985
Tachyarrhythmias associated with programmable automatic atrial antitachycardia pacemakers. 1983
Clinical spectrum of pericardial effusion as the presenting feature of hypothyroidism. 1983
Supraventricular tachycardia associated with nodoventricular and concealed atrioventricular bypass tracts. 1982
Management of endomyocardial fibrosis: successful surgical treatment of biventricular involvement and consideration of the superiority of operative intervention. 1981
Clinical pathologic conference: heart neoplasm. 1975
Rationale and design of the Dynamic Coronary Roadmap for Contrast Reduction (DCR4Contrast) in PCI randomized controlled trial.. 263. 2023
Postoperative pericardial effusion, pericardiotomy, and atrial fibrillation: An explanatory analysis of the PALACS trial.. 260. 2023
Inflammation biomarkers and incident coronary heart disease: the Reasons for Geographic And Racial Differences in Stroke Study.. 253. 2022
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations.. 241. 2021
Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy?. 239. 2021
Cardiac transplantation outcomes in patients with amyloid cardiomyopathy.. 236. 2021
Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial.. 228. 2020
Mild sleep restriction increases 24-hour ambulatory blood pressure in premenopausal women with no indication of mediation by psychological effects.. 223. 2020
Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation.. 222. 2020
The effect of metoprolol and aspirin on cardiovascular risk in bereavement: A randomized controlled trial.. 220. 2019
High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction.. 220. 2019
Association of 25-hydroxyvitamin D with incident coronary heart disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.. 217. 2019
C-reactive protein and stroke risk in blacks and whites: The REasons for Geographic And Racial Differences in Stroke cohort.. 217. 2019
Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry.. 216. 2019
The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale.. 216. 2019
C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.. 210. 2019
Comparison of automated interval measurements by widely used algorithms in digital electrocardiographs.. 200. 2018
Fine particulate matter and incident coronary heart disease in the REGARDS cohort.. 197. 2017
Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale.. 190. 2017
Time to achieving therapeutic international normalized ratio increases hospital length of stay after heart valve replacement surgery.. 187. 2017
Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS).. 181. 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.. 179. 2016
Variation in use of echocardiography among veterans who use the Veterans Health Administration vs Medicare.. 170. 2015
Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease.. 170. 2015
Trends in mortality and recurrent coronary heart disease events after an acute myocardial infarction among Medicare beneficiaries, 2001-2009.. 170. 2015
Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.. 169. 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.. 169. 2015
Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial.. 169. 2015
A nationwide survey on perception, experience, and expectations of hybrid coronary revascularization among top-ranked US hospitals.. 169. 2015
Association of ideal cardiovascular health and calcified atherosclerotic plaque in the coronary arteries: the National Heart, Lung, and Blood Institute Family Heart Study.. 169. 2015
Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI.. 169. 2014
Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells.. 168. 2014
Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: an analysis of intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI).. 169. 2014
Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry.. 167. 2013
Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.. 166. 2013
Comparison of automated measurements of electrocardiographic intervals and durations by computer-based algorithms of digital electrocardiographs.. 167. 2013
Prognostic implications of procedural vs spontaneous myocardial infarction: results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry.. 166. 2013
Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial.. 166. 2013
Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers.. 166. 2013
Red cell distribution width as a bleeding predictor after percutaneous coronary intervention.. 166. 2013
Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial.. 166. 2013
Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.. 165. 2012
Does clinical presentation affect outcome among patients with acute coronary syndromes undergoing percutaneous coronary intervention? Insights from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study.. 164. 2012
Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-T for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the "Rule Out Myocardial Infarction using Computer Assisted Tomography" (ROMICAT) trial.. 163. 2012
Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database.. 163. 2012
Design of the Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department.. 163. 2012
Mode of death after contemporary percutaneous coronary intervention: a report from the Evaluation of Drug Eluting Stents and Ischemic Events registry.. 162. 2011
Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: the harmonizing outcomes with revascularization and stents in AMI (HORIZONS-AMI) trial.. 162. 2011
The National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC): results from phase I and scientific opportunities in phase II.. 162. 2011
A multicenter comparison of established and emerging cardiac biomarkers for the diagnostic evaluation of chest pain in the emergency department.. 162. 2011
Association of health insurance status with presentation and outcomes of coronary artery disease among nonelderly adults undergoing percutaneous coronary intervention.. 162. 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction".. 162. 2011
Changes in reference vessel diameter in ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: implications for appropriate stent sizing.. 162. 2011
Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry.. 161. 2011
Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era.. 160. 2010
Heart rate is associated with red blood cell fatty acid concentration: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study.. 159. 2010
Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.. 159. 2010
Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.. 159. 2010
Impact of computerized dosing on eptifibatide-associated bleeding and mortality.. 158. 2009
Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository.. 158. 2009
Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.. 158. 2009
Association of aortic valve calcification to the presence, extent, and composition of coronary artery plaque burden: from the Rule Out Myocardial Infarction using Computer Assisted Tomography (ROMICAT) trial.. 158. 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.. 158. 2009
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.. 157. 2009
Implantable cardioverter-defibrillator deactivation at the end of life: a physician survey.. 157. 2009
Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial.. 157. 2009
Adverse association between diabetic retinopathy and cardiac structure and function.. 157. 2008
Platelet reactivity and response to aspirin in subjects with the metabolic syndrome.. 156. 2008
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.. 157. 2008
Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents.. 155. 2008
Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report.. 155. 2008
Ethnicity and socioeconomic status influence use of primary angioplasty in patients presenting with acute myocardial infarction.. 154. 2007
Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease.. 154. 2007
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.. 154. 2007
Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.. 154. 2007
Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.. 153. 2007
Effect of oral beta-blocker therapy on microvolt T-wave alternans and electrophysiology testing in patients with ischemic cardiomyopathy.. 153. 2007
Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction.. 153. 2007
Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials.. 152. 2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.. 152. 2006
Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States.. 152. 2006
Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS).. 152. 2006
Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative.. 152. 2006
Impact of organizational infrastructure on beta-blocker and aspirin therapy for acute myocardial infarction.. 152. 2006
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.. 152. 2006
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.. 152. 2006
Effects of a statewide physician-led quality-improvement program on the quality of cardiac care.. 151. 2006
Recursive partitioning-based preoperative risk stratification for atrial fibrillation after coronary artery bypass surgery.. 151. 2006
Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS).. 151. 2006
Impact of race and ethnicity on inhospital outcomes after percutaneous coronary intervention (report from the 2000-2001 New York State Angioplasty Registry).. 151. 2006
Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era.. 150. 2005
The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: a multicenter radionuclide study.. 150. 2005
Identification of a novel 5-base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy.. 150. 2005
Percent change in B-type natriuretic peptide levels during treadmill exercise as a screening test for exercise-induced myocardial ischemia.. 150. 2005
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).. 150. 2005
The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial.. 150. 2005
Two-year clinical follow-up of 90Sr/90 Y beta-radiation versus placebo control for the treatment of in-stent restenosis.. 149. 2005
GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention.. 148. 2004
Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.. 148. 2004
Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.. 148. 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.. 148. 2004
Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT.. 148. 2004
Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy.. 146. 2003
Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial.. 146. 2003
Prognostic implications of ejection fraction from linear echocardiographic dimensions: the Strong Heart Study.. 146. 2003
Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.. 146. 2003
Associations of aortic and mitral regurgitation with body composition and myocardial energy expenditure in adults with hypertension: the Hypertension Genetic Epidemiology Network study.. 145. 2003
Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART).. 145. 2003
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.. 145. 2003
Adjusting for patient differences in predicting hospital mortality for percutaneous coronary interventions in the Clinical Outcomes Assessment Program.. 145. 2003
Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study.. 145. 2003
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.. 144. 2002
Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension.. 144. 2002
Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction.. 143. 2002
Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study.. 143. 2002
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).. 143. 2002
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists.. 143. 2002
Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.. 143. 2002
Myocardial function and geometry in hypertensive subjects with low levels of afterload.. 143. 2002
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.. 143. 2002
Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction.. 143. 2002
Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial.. 143. 2002
Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.. 142. 2001
Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study.. 141. 2001
Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.. 141. 2001
A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study.. 141. 2001
Dalteparin in combination with abciximab during percutaneous coronary intervention.. 141. 2001
Prognostic implications of left ventricular hypertrophy.. 141. 2001
Formal analysis of the optimal duration of tilt testing for the diagnosis of neurally mediated syncope.. 141. 2001
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.. 140. 2000
Underutilization of oral anticoagulant therapy for stroke prevention in elderly patients with heart failure.. 140. 2000
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.. 139. 2000
Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials.. 139. 2000
Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.. 138. 1999
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion.. 137. 1999
Heart rate changes preceding ventricular ectopy in patients with ventricular tachycardia caused by reentry, triggered activity, and automaticity.. 136. 1998
Progressive deterioration of coronary flow reserve after heart transplantation.. 136. 1998
Coronary flow reserve may predict myocardial recovery after myocardial infarction in patients with TIMI grade 3 flow.. 136. 1998
Effects of intraaortic balloon counterpulsation on carotid artery blood flow.. 135. 1998
Effects of adenosine on left ventricular filling dynamics in patients with and without coronary artery disease: a Doppler echocardiographic study.. 135. 1998
JNC V revisited: standard of care or individualized treatment for hypertension?. 135. 1998
Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.. 135. 1998
Precordial QT dispersion and inducible ventricular tachycardia.. 134. 1997
Transthoracic three-dimensional echocardiographic reconstruction of left and right ventricles: in vitro validation and comparison with magnetic resonance imaging.. 133. 1997
Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning.. 132. 1996
Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients.. 132. 1996
Combined rest and exercise electrocardiographic repolarization findings in relation to structural and functional abnormalities in asymptomatic aortic regurgitation.. 132. 1996
Lack of association between mitral valve prolapse and history of rheumatic fever.. 131. 1996
Improved detection of cardiac contusion with cardiac troponin I.. 131. 1996
Vascular effects of diet-induced hypercalcemia after balloon artery injury in giant Flemish rabbits.. 130. 1995
Performance of the signal-averaged electrocardiogram: relation to baseline QRS duration.. 129. 1995
Lymphocyte G proteins reflect response to treatment in congestive heart failure.. 129. 1995
Differential therapeutic responses of patients with isoproterenol-dependent and isoproterenol-independent vasodepressor syncope.. 128. 1994
Electrocardiographic repolarization measurements at rest and during exercise in normal subjects and in patients with coronary artery disease.. 128. 1994
Normalization of cardiac structure and function after regression of cardiac hypertrophy.. 128. 1994
Dobutamine stress echocardiography: sensitivity, specificity, and predictive value for future cardiac events.. 127. 1994
Transesophageal echocardiography in critically ill patients: feasibility, safety, and impact on management.. 127. 1994
Prostaglandin E1 does not accelerate rTPA-induced thrombolysis in acute myocardial infarction.. 127. 1994
Population selection and performance of the exercise ECG for the identification of coronary artery disease.. 127. 1994
Assessment of regional myocardial perfusion with myocardial contrast echocardiography in a canine model of varying degrees of coronary stenosis.. 127. 1994
Comparison of teboroxime and thallium for the reversibility of exercise-induced myocardial perfusion defects.. 126. 1993
Acceleration of atrioventricular conduction during corticosteroid therapy.. 125. 1993
Value and limitations of heart rate-adjusted ST segment depression criteria for the identification of anatomically severe coronary obstruction: test performance in relation to method of rate correction, definition of extent of disease, and beta-blockade.. 125. 1993
Doppler assessment of right ventricular filling dynamics in systemic hypertension: comparison with left ventricular filling.. 124. 1992
Coronary risk factors and the severity of angiographic coronary artery disease in members of high-risk pedigrees.. 123. 1992
Contrast opacification of left ventricular myocardium following intravenous administration of sonicated albumin microspheres.. 122. 1991
Effect of atenolol on myocardial infarct expansion in a nonreperfused rat model.. 122. 1991
Use of adenosine echocardiography for diagnosis of coronary artery disease.. 122. 1991
The effect of enteric-coated aspirin on the morning increase in platelet activity.. 121. 1991
Hypertensive heart disease: relationship of silent ischemia to coronary artery disease and left ventricular hypertrophy.. 120. 1990
Factors influencing the outcome of balloon aortic valvuloplasty in the elderly.. 120. 1990
Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination.. 120. 1990
Effect of baseline ST segment elevation on test performance of standard and heart rate-adjusted ST segment depression criteria.. 119. 1990
Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction.. 119. 1990
Comparison of quantitative coronary angiography to visual estimates of lesion severity pre and post PTCA.. 119. 1990
Relationship of atrial natriuretic factor to left ventricular volume and mass.. 118. 1989
Reversal of left ventricular dilatation, hypertrophy, and dysfunction by valve replacement in aortic regurgitation.. 118. 1989
The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio.. 118. 1989
Prognostic significance of the signal-averaged ECG depends on the time of recording in the postinfarction period.. 118. 1989
Nonventricular arrhythmias as precursors of ventricular fibrillation in patients with out-of-hospital cardiac arrest.. 118. 1989
Effect of ambulatory blood pressure monitoring on the diagnosis and cost of treatment for mild hypertension.. 116. 1988
Accurate assessment of aortic stenosis severity by Doppler echocardiography independent of aortic jet velocity.. 116. 1988
Identification of anatomically extensive coronary artery disease by the exercise ECG ST segment/heart rate slope.. 115. 1988
Prevalence and clinical correlates of non-Wenckebach, narrow-complex second-degree atrioventricular block detected by ambulatory ECG.. 115. 1988
Ambulatory monitoring of blood pressure as a predictor of cardiovascular risk.. 114. 1987
Assessment of left ventricular diastolic filling by two-dimensional echocardiography.. 113. 1987
Mitral valve prolapse and infective endocarditis.. 113. 1987
Relationship of the electrocardiographic response to exercise to geometric and functional findings in aortic regurgitation.. 113. 1987
Evaluation of coronary artery disease by an improved method of exercise electrocardiography: the ST segment/heart rate slope.. 112. 1986
Hemodynamic effects of moricizine at rest and during supine bicycle exercise: results in patients with ventricular tachycardia and left ventricular dysfunction.. 112. 1986
Relation between the presence of echocardiographic vegetations and the complication rate in infective endocarditis.. 112. 1986
Evaluation of the aorta in the Marfan syndrome by magnetic resonance imaging.. 111. 1986
Mitral valve prolapse and hyperthyroidism: effect of patient selection.. 110. 1985
Mitral-septal angle: a new two-dimensional echocardiographic index of left ventricular performance.. 110. 1985
Electrophysiologic evaluation of syncope in patients with bifascicular block.. 106. 1983
Mitral valve prolapse in the general population. 1. Epidemiologic features: the Framingham Study.. 106. 1983
Mitral valve prolapse in the general population. 2. Clinical features: the Framingham Study.. 106. 1983
Mitral valve prolapse in the general population. 3. Dysrhythmias: the Framingham Study.. 106. 1983
Ethmozine suppression of single and repetitive ventricular premature depolarizations during therapy: documentation of efficacy and long-term safety.. 106. 1983
Effect of cardiac surgery on ventricular septal motion: assessment by intraoperative echocardiography and cross-sectional two-dimensional echocardiography.. 104. 1982
Coronary artery surgery in diabetics: 261 consecutive patients followed four to seven years.. 104. 1982
Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic relative wall thickness: identification of severe valvular aortic stenosis in adult patients.. 103. 1982
Septal myocardial perfusion imaging with thallium-201 in the diagnosis of proximal left anterior descending coronary artery disease.. 102. 1981
Effect of exercise training on plasma high-density lipoprotein cholesterol in coronary disease patients.. 101. 1981
Sequential postoperative assessment of left ventricular performance with gated cardiac blood pool imaging following aortocoronary bypass surgery.. 101. 1981
The control of hypertension in the community: no easy solution.. 97. 1979
Hemorrhagic myocardial infarction associated with aortocoronary bypass revascularization.. 96. 1978
Fine flutterings of the aortic valve as demonstrated by aortic valve echocardiograms.. 95. 1978
Aortic valve closure: echocardiographic, phonocardiographic, and hemodynamic assessment.. 91. 1976
An analysis of the left ventricular response to isometric exercise.. 88. 1974
What do we mean by "outcome can be predicted"? 2008
Dynamic QT dispersion during exercise. 1998
Detection of abnormal LV function in mitral regurgitation by echographic mitral-septal separation. 1982
Hypertension control: an alternative view from Gimbels. 1978
Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: a Cardiac Safety Research Consortium "Incubator" Think Tank. 2010
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. 2002
Resistance or resistors? Has Ohm's law come to antiplatelet therapy?. 159. 2010
The pain and the gain of treating patients with acute coronary syndromes-can the two be separated?. 157. 2009
Much ado about thrombin.. 137. 1999
On the matter of method in exercise testing.. 127. 1994
Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis. 2017
Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet). 2015
Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. 2015
Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials. 2013
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. 2012
Medication adherence: a call for action. 2011
The Cardiac Safety Research Consortium electrocardiogram warehouse: thorough QT database specifications and principles of use for algorithm development and testing. 2010
Insights into the pathophysiology of ST-elevation myocardial infarction. 2006
Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluder. 2006
Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. 2004
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. 2004
High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. 2002
New options in lipid management--can we extend the benefits of current therapy? Introduction. 2002
Therapeutic options in minimizing left ventricular hypertrophy. 2000
Viral activation of the coagulation cascade. 1999
Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. 1999
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. 1998
Relation between inhibition of platelet aggregation and clinical outcomes. 1998
Chronic venous insufficiency: mechanisms and management. 1996
Acute myopericarditis resulting from Lyme disease. 1995
Solid-angle theory and heart rate adjustment of ST-segment depression for the identification and quantification of coronary artery disease. 1994
The role of the coronary collateral circulation in limiting myocardial ischemia and infarct size. 1993
The cardiologist's approach to evaluation and management of the patient with essential hypertension. 1993
Management of myocardial infarction shock: current status. 1989
Relationship between ambulatory and exercise blood pressure and cardiac structure. 1988
Role of Doppler and imaging echocardiography in selection of patients for cardiac valvular surgery. 1987
Arrhythmias and sudden death in mitral valve prolapse. 1987
Diagnosis and classification of severity of mitral valve prolapse: methodologic, biologic, and prognostic considerations. 1987
Combined vasodilator and inotropic therapy of heart failure: experimental and clinical concepts. 1981

VIVO Weill Cornell Medical College

American heart journal Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)